drugset
Drugs / Seasonal trivalent inactivated influenza vaccine
last change Jun 2021 re-read 3 minutes ago

Seasonal trivalent inactivated influenza vaccine

also known as IIV3 · TIV

Vaccine

Developed for
influenza
Investigated by
Centers for Disease Control and Prevention · PATH · Research Institute for Development · Institut Pasteur

Trials 2

today NCT01819155 · Ph 2 NCT00893906 · Ph 4
2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT01819155 Apr → Sep 2013 influenza PATH Completed No outcome recorded
Phase 41 trial
Phase 4 NCT00893906 May 2009 → Dec 2012 influenza PATH Completed Mixed

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Seasonal trivalent inactivated influenza vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT01819155 ↗
1

NCT00893906 ↗
Known as IIV3 “BACKGROUND: We report results of years 2 and 3 of consecutive cluster-randomized controlled trials of trivalent inactivated influenza vaccine (IIV3) in Senegal.” PMID 33165566 ↗ Jun 2021
Known as TIV “A single dose of trivalent inactivated influenza vaccine (TIV) is 70 to 90 percent effective in preventing influenza” NCT00893906 ↗
Modality Vaccine “single dose of trivalent inactivated influenza vaccine (TIV)” NCT00893906 ↗